Navigation Links
Velcade (Bortezomib) for Injection Based Therapies Produced,Complete Remission Rates as High as 54 Percent in Patients With,Previously Treated Multiple Myeloma

tion about VELCADE clinical trials, patients and physicians can contact the Millennium Medical Product Information Department at 1-866-VELCADE (1-866-835-2233).

About Millennium

Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company based in Cambridge, Mass., markets VELCADE, a novel cancer product, and has a robust clinical development pipeline of product candidates. Millennium's research, development and commercialization activities are focused in two therapeutic areas: oncology and inflammation. By applying its knowledge of the human genome, understanding of disease mechanisms and industrialized drug discovery platform, Millennium is developing an exciting pipeline of innovative product candidates. Millennium's website is www.millennium.com.

This press release contains "forward-looking statements," including statements about the Company's growth and development of products. Various important risks may cause the Company's actual results to differ materially from the results indicated by these forward-looking statements, including: adverse results in its drug discovery and clinical development programs; failure to obtain patent protection for its discoveries; commercial limitations imposed by patents owned or controlled by third parties; the Company's dependence upon strategic alliance partners to develop and commercialize products and services based on its work; difficulties or delays in obtaining regulatory approvals to market products and services resulting from its development efforts; product withdrawals; competitive factors; difficulties or delays in manufacturing the Company's products; government and third-party reimbursement rates; the commercial success of VELCADE and INTEGRILIN(R) (eptifibatide) Injection; achieving revenue consistent with internal forecasts; and the requirement for substantial funding to conduct research and development and to expand commercial
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
2. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
3. Velcade (bortezomib) for Injection Survival Data in Front-Line Multiple Myeloma Patients to be Featured at 11th International Myeloma Workshop
4. Study Shows Velcade Plus Doxil Improves Survival in Previously Treated Patients With Multiple Myeloma
5. New Data on Market-Leading Velcade (Bortezomib) for Injection Further Strengthen Role in Previously Treated Multiple Myeloma
6. Millennium Discovers Biomarkers Potentially Predictive of Response to Velcade (Bortezomib) for Injection
7. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
8. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
9. Genta Announces Results of Phase 1 Study Using Genasense Administered by Intermittent Subcutaneous Injection
10. Aquavan (Fospropofol Disodium) Injection Data Presented at Digestive Disease Week 2007
11. Hana Biosciences Announces Data to be Presented On Talvesta (Talotrexin) for Injection at The American Association for Cancer Research Annual Meeting
Post Your Comments:
(Date:9/4/2015)... India , September 4, 2015 ... Market by Application (Plasmapheresis, Plateletpheresis, Erythrocytapheresis, Leukapheresis, and Photopheresis) ... Technology and by Product - Global Forecast to 2020", ... to reach USD 2.5 Billion by 2020, growing at ... 2015 to 2020. Browse 139 Tables ...
(Date:9/4/2015)... Future Prospects for Companies in Antihistamines, Corticosteroids, ... - new study showing you trends, partnerships, and ... allergic rhinitis drugs heading? What are the commercial prospects ... you potential revenues and other trends to 2025, discussing ... report provides 273 tables, charts, and graphs. Discover the ...
(Date:9/4/2015)... Research and Markets ( http://www.researchandmarkets.com/research/gbd3bt/stability_testing ) ... of Pharmaceuticals (London, UK - December 2-3, 2015)" ... comprehensive two day seminar delegates will: - ... suitable for global arketing - Be able to ... and facilities - Know how to save resource ...
Breaking Medicine Technology:Apheresis Market Worth 2.5 Billion USD by 2020 2Apheresis Market Worth 2.5 Billion USD by 2020 3Apheresis Market Worth 2.5 Billion USD by 2020 4Apheresis Market Worth 2.5 Billion USD by 2020 5Allergic Rhinitis Drugs Market Forecast 2015-2025 2Allergic Rhinitis Drugs Market Forecast 2015-2025 3Allergic Rhinitis Drugs Market Forecast 2015-2025 4Allergic Rhinitis Drugs Market Forecast 2015-2025 5Allergic Rhinitis Drugs Market Forecast 2015-2025 6Allergic Rhinitis Drugs Market Forecast 2015-2025 7Stability Testing of Pharmaceuticals: 2 Day Seminar - London, UK - December 2-3, 2015 2
(Date:9/4/2015)... , ... September 04, 2015 , ... Having access to ... has led to an increasing amount of unnecessary emergency room visits which affects hospitals’ ... taxes the country’s health bill. Fortunately, a solution to alleviate this problem has recently ...
(Date:9/4/2015)... ... September 04, 2015 , ... Steven Winter Associates, Inc., ... has been selected for the Residential Award of Merit by the Connecticut Green ... Chosen from a highly competitive field of submissions, the net-zero energy residence will ...
(Date:9/4/2015)... ... 2015 , ... FiltersFast.com, the online retail leader in air ... up. FiltersFast.com, will ship all orders over $50.00 for free. Use this ... advantage of this promotion now through September 8, 2015. , Filtersfast.com offers a ...
(Date:9/3/2015)... (PRWEB) , ... September 04, 2015 , ... AlignLife ... of September. , "There are so many children and adults who don't have ... says Dr. Sara Mahalko-Leonhardt. "We love holding our annual Coat Drive to help those ...
(Date:9/3/2015)... ... 2015 , ... TransPack Toon gives users a set of 90 cartoon transitions ... transitions in 30 different styles. Presets range from snow, underwater, forest, futuristic, city and ... Toon features 90 cartoon transitions from 30 unique styles. Editors can choose between ...
Breaking Medicine News(10 mins):Health News:Telemedicine Platform DocChat Announces Launch Offering a Way for Patients to Consult Doctors and Receive Prescriptions 24/7 2Health News:Telemedicine Platform DocChat Announces Launch Offering a Way for Patients to Consult Doctors and Receive Prescriptions 24/7 3Health News:South Glastonbury Home Selected for Award by Connecticut Green Building Council 2Health News:FiltersFast.com Wows with a Long Labor Day Weekend Shipping Offer 2Health News:AlignLife is Helping to Keep the Community Warm This Winter 2Health News:Pixel Film Studios Releases TransPack Toon, a New FCPX Transition 2
... these factors influence how likely they are to ... Racial and ethnic variations in how women perceive their ... get screened for cancer, particularly colon cancer, says a ... researchers interviewed 1,160 women, ages 50 to 80, about ...
... In Time For Summer, CINCINNATI, April 15 ... Americans beautify their insides this summer,with the addition of ... lineup. Pink Lemonade joins Berry Burst and Orange flavors ... 100 percent,fiber from psyllium husk making it a delicious ...
... 15 Gentiva Health,Services, Inc. (Nasdaq: GTIV ), ... services, today announced that it has,scheduled a conference call ... 10:00,a.m. ET to discuss operating results for the first ... financial news release the morning of May,1 before pre-market ...
... OF APPROXIMATELY $3.10-$3.20 PER ... DILUTED SHARE, NEW ... pharmaceutical company, today announced that,fully diluted earnings per share (EPS) for the ... share include a,charge of $110,138,000, or $0.35 per share net of tax, ...
... cancer drug Sutent may slow liver cancer progression, scientists ... A new drug duo might help prevent colorectal cancer, ... the progression of liver cancer. , So conclude two ... Research annual meeting in San Diego. , In the ...
... April 15 Wellcorps International, one of,the nations ... a major paper on the history and evolution ... can be found in its entirety at, http://www.wellcorps.com ... Tony Rich and noted,clinical medical anthropologist Meg Jordan, ...
Cached Medicine News:Health News:Women's Awareness of Cancer Risk Linked to Race, Ethnicity 2Health News:Quench Your Summer Thirst...With Fiber 2Health News:Quench Your Summer Thirst...With Fiber 3Health News:Gentiva(R) Health Services Schedules First Quarter Earnings Call and Web Cast for Thursday, May 1, 2008 2Health News:Gentiva(R) Health Services Schedules First Quarter Earnings Call and Web Cast for Thursday, May 1, 2008 3Health News:Forest Laboratories, Inc. Reports Fiscal Year 2008 Fourth Quarter Reported EPS of $0.55 Including $0.35 Per Share Charge for Licensing Payment 2Health News:Forest Laboratories, Inc. Reports Fiscal Year 2008 Fourth Quarter Reported EPS of $0.55 Including $0.35 Per Share Charge for Licensing Payment 3Health News:Forest Laboratories, Inc. Reports Fiscal Year 2008 Fourth Quarter Reported EPS of $0.55 Including $0.35 Per Share Charge for Licensing Payment 4Health News:Forest Laboratories, Inc. Reports Fiscal Year 2008 Fourth Quarter Reported EPS of $0.55 Including $0.35 Per Share Charge for Licensing Payment 5Health News:Forest Laboratories, Inc. Reports Fiscal Year 2008 Fourth Quarter Reported EPS of $0.55 Including $0.35 Per Share Charge for Licensing Payment 6Health News:Forest Laboratories, Inc. Reports Fiscal Year 2008 Fourth Quarter Reported EPS of $0.55 Including $0.35 Per Share Charge for Licensing Payment 7Health News:Forest Laboratories, Inc. Reports Fiscal Year 2008 Fourth Quarter Reported EPS of $0.55 Including $0.35 Per Share Charge for Licensing Payment 8Health News:Forest Laboratories, Inc. Reports Fiscal Year 2008 Fourth Quarter Reported EPS of $0.55 Including $0.35 Per Share Charge for Licensing Payment 9Health News:New Drug Duo Helps Fight Colon Cancer 2Health News:New Drug Duo Helps Fight Colon Cancer 3Health News:New Drug Duo Helps Fight Colon Cancer 4Health News:Wellcorps International Releases Major Paper on History and Evolution of Amphetamine and Anti-Depressant Use in America 2
Custom Conjugation Services...
Colloidal Gold Conjugated, Streptavidin - 50 OD...
Colloidal Gold Conjugated, Goat anti-rabbit IgG (H&L) - 12 OD...
Colloidal Gold Conjugated, Goat anti-mouse IgG (H&L) - 50 OD...
Medicine Products: